Publications

  1. Casanueva FF, Borras CG, Burguera B, Muruais C, Fernandez M, Devesa J. Steroids and neuroendocrine function in anorexia nervosa.  J Steroid Biochem 1987; 27:635-640.
  2. Casanueva FF, Borras CG, Burguera B, Lima L, Muruais C, Tresguerres JAF, Devesa J.  Growth hormone and prolactin secretion after GHRH administration in anorexia nervosa patients, normal controls and normal controls pretreated with tamoxifen.  Clin Endocrinol 1987; 27:517-523.
  3. Casanueva FF, Burguera B, Tome M, Lima L, Treguerres JAF, Devesa J, Dieguez C.  Depending on the time of administration, dexamethasone potentiates or blocks growth hormone releasing hormone-induced growth hormone release in man.  Neuroendocrinology 1989; 47:46-49.
  4. Peñalva A, Burguera B, Casabiell X, Tresguerres JAF, Dieguez C, Casanueva FF.  Activation of cholinergic neurotransmission by pyridostigmine, reverses the inhibitory effect of hyperglycaemia on growth hormone releasing hormone-induced GH secretion in man; suggesting that glucose acts through hypothalamic release of somatostatin. Neuroendocrinology 1989; 49:551-554.
  5. Burguera B, Muruais C, Peñalva A, Casanueva FF, Dieguez C. Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in manNeuroendocrinology 1990; 51:58-62.
  6. Casanueva FF, Burguera B, Muruais C, Dieguez C.  Acute administration of glucocorticoids: a new and peculiar stimulus of growth hormone secretion in man. J Clin Endocrinol Metab 1990; 70:234-237.
  7. Burguera B, Werner H, Sclar M, Shen-Orr Z, Stannard B, Roberts Jr CT, Nissley SP, Vore SH, Caro JF, LeRoith D.  Liver regeneration is associated with increased expression of the insulin-like growth factor II/mannose 6-phosphate receptor.  Mol Endocrinol 1990: 4:1539-1545.
  8. Burguera B, Couce M, Lage M, Vina MD, Dieguez C, Casanueva FF.  Lack of effect of TRH secretion of growth hormone induced by dexamethasone.Rev Clin Esp 1990; 188:65-67.
  9. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts Jr., CT, LeRoith D. Regulation of insulin-like growth factor receptors gene expression in diabetic kidney. Diabetes 1990;39: 1490-1497.
  10. Benitez L, Mallo F, Alvarez C, Burguera B, Sanchez-Franco F, Dieguez C. Estrogen-dependent effects of bombesin on in vivo growth hormone secretion in the rat. Neuroendocrinology 1991;52:608-703.
  11. Alvarez C, Mallo F, Burguera B, Cacicedo L, Dieguez C, Casanueva FF. Evidence for a direct pituitary inhibition by free fatty acids of in vivo growth hormone responses of GHRH in the rat. Neuroendocrinology 1991;53:185-189.
  12. Burguera B, Long S, Frank HB, DiMarchi R, Caro JF.  Binding of insulin-like growth factors, proinsulin and proinsulin analogs to human liver, muscle and adipose tissue receptors.J Clin Endocrinol Metab 1991; 72:1238-1241.
  13. Burguera B, Madigan T, Mustafa SJ, Frank HB, DiMarchi R, Caro JF.  The interaction of proinsulin with insulin-like growth factors I and II receptors in smooth muscle membranes from bovine coronary arteries.Av Diabetol1992; 5:187-196.
  14. Usala AI, Madigan T, Burguera B, Sinha MK, Caro JF, Powell JG, Butler PC. Insulin-like growth factor I treatment of ketoacidosis in an insulin-resistant adolescent with type I diabetes mellitus. New Engl J Med 1992; 327:853-857.
  15. Casanueva FF, Burguera B, Alvarez CU, Zugaza JL, Pombo M, Dieguez C. Corticoids as a new stimulus of growth hormone secretion in man. J Ped Endocrinol 1992; 5:85-90.
  16. LeRoith D, Werner H, Burguera B, Roberts Jr, CT, Mulroney S, Haramati A.The insulin-like growth factor family of peptides, binding proteins and receptors: their potential  role     in tissue regeneration.  Advances in Experimental Medicine and Biology, 1992;21-30.
  17. Mayo F, Alvarez CU, Benitez L, Burguera B, Coya R, Casanueva FF, Dieguez C.  Regulation of GHRP-6 induced GH secretion in the rat. Neuroendocrinology 1993; 57:247-256.
  18. Burguera B, Dudek R, Couce ME, Slieker ZT, Heath WF, Caro JF.  Glut-2 expression in the liver is up-regulated by glucose administration.Av Diabetol1993; 7:23-26.
  19. Burguera B, Tapscott EB, Elton CW, Usala AL, Pories CW, Sakano K, Dohm GL.  IGF-II stimulation of glucose uptake in human muscle is not mediated by IGF-II receptor (IGF-II/man 6-PR). Biochem J 1994;300:781-785.
  20. Usala AL, Madigan T, Burguera B, Sinha MK, Powell JC, Usala SJ. Intravenous, but not subcutaneous, insulin-like growth factor I induces sustained insulin sensitivity in type I diabetes mellitus complicated by severe resistance. J Clin Endocrinol Metab 1994; 79:435-440.
  21. Burguera B.  IGF-I treatment in extreme insulin-resistance syndromes.Ann Int Med.1994; 121:549-550.
  22. Burguera B, Dudek RW, Caro JF.  Liver GLUT-2 protein is not upregulated in non-insulin-dependent diabetes. Hom Metab Res.1995;27:341-343.
  23. Guo Z., Nielsen S., Burguera B, Jensen MD Free fatty acid turnover measured using ultralow doses of [U-13C] Palmitate. 1997. J  Lipid Res 38:1888-95
  24. Couce ME, BurgueraB, ParisiJE, JensenMD, LloydRV.Localization of the leptin receptor (OB-R) in the human brain. 1997.  Neuroendocrinology. 66:145-50
  25. Thomas T, Gori F, Jensen MD, Burguera B, Riggs BL. 1999. Leptin acts on human marrow stroma cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology.140:1630-1638
  26. L. Jin, Burguera B, Couce ME, Lamsam J, K. Kovacs, Lloyd RV. 1999 Leptin receptor  (OB-Rb) expression in normal and neoplastic human pituitaries. Regulation of pituitary cell proliferation by leptin.. J Clin Endocrinol Metab 84:2903-2911
  27. Burguera B and Garib H. THYROID INCIDENTALOMAS. Diagnostic and therapeutic approach.  2000. Endocrinology and Metabolism Clinics of North America. 29:187-203.
  28. Burguera  B, Proctor D, Dietz N, Guo Z, Joyner M, Jensen M. Leg free fatty acid kinetics during exercise in men and women. 2000. Am J Physiol Endocrinol Metab 278:E113-E117
  29. Burguera B, Couce ME, Long  J, Lamsam J, Parisi JE, Lloyd RV. 2000 The long form of the  leptinreceptor  (OB-Rb) is widely expressed in the human brain. Neuroendocrinology. 61:187-195
  30. L. Jin, Burguera B, Couce ME, K. Kovacs, Lloyd RV. Leptin receptor  (OB-Rb) expression in rat pituitaries. Endocrinology 2000 Jan; 141:333-339.
  31. Thomas T, Burguera B, Melton LJ, Atkinson EJ,  Riggs BL. Khosla S. Relationship of serum leptin levels with body composition, sex steroids and insulin levels in men and women. 2000. Metabolism . 49:1278-1284
  32. Burguera B, Curran G, Couce ME, Lamsam J, Cleary M, Poduslo J. Obesity is associated with a decreased of leptin transport across the blood brain barrier and up regulation of  leptin receptor in the hypothalamus. 2000. Diabetes. 49:1219-1223
  33. Burguera B& Couce ME. 2000. Leptin access into the brain: a saturated transport   system vs. a post-receptor defect in obesity. J Clin Invest. e-letter.
  34. Nielsen S, Hensrud DD, Romanski S, Levine JA, Burguera B, Jensen MD.Body composition and resting energy expenditure in humans: role of fat, fat-free mass and extracellular fluid. Int J Obes Relat Metab Disord 2000 24:1153-1157
  35. Thomas T,  Burguera B, Melton LJ, Atkinson EJ, Riggs BL, Khosla S. 2001. Serum leptin levels and bone mineral density are directly related in women but not in men. In press.Bone. 29:114-120.
  36. Vidal S, Cohen SM, Horvath E, Kovacs K, Scheithauer BW, Burguera BG, Lloyd RV Subcellular localization of leptin in non-tumorous and adenomatous human pituitaries: an immuno-ultrastructural study. J Histochem Cytochem 2000 48:1147-52
  37. Burguera B ,Thomas T, Gori F, Evans G, , Riggs BL, Khosla S, Turner RT. Leptin inhibits bone resoption  in vivo. 2001. Endocrinology. 142:3546-53
  38. Burguera B, Couce ME.  Leptin Access into the Brain: a Saturated Transport Mechanism in Obesity. 2001. Physiol Behav. 74:717-20.
  39. Couce ME, Green D, Brunetto A, Achim C, Lloyd RV, Burguera B.Limited brain access for leptin in obesity. 2002. Pituitary 4:101-104
  40. Lloyd RV, Jin L, Tsumanuma I, Vidal S,  Kovacs E, Scheithauer B, Couce M, Burguera B. Leptin and Leptin receptor in anterior pituitary function. 2002. Pituitary 4: 33-48
  41. Thomas T, Burguera B. Is leptin the link between fat and bone mass? 2002. J Bone Miner Res. 2002 17:1563-9.
  42. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. 2003. Ann Surg. 238:467-84
  43. Couce ME, Burguera B. Obesidad y Diabetes Mellitus Tipo 2: Un autentico Problema Macrosanitario. Medicina Clinica. 2004; 5 :3-6
  44. Couce ME, Cottam DR, Teijeiro R, Esplen J, Schauer P, Burguera B Potential role of hypothalamic ghrelin in the pathogenesis of human obesity. J Endocrinol Invest 2006. 29:599-605
  45. Couce ME, Cottam DR, Teijeiro R, Esplen J, Schauer P, Burguera B. Impact of Gastric Bypass Surgery on plasma ghrelin levels. A negative answer. Obes Surg. 2006 16:870-8.
  46. BurgueraB, BrunettoA, Garcia-OcanaA, TeijeiroR, EsplenJ, ThomasT, CouceME, ZhaoA. Leptin increases proliferation of human osteosarcoma cells through activation of PI(3)-K and MAPK pathways. Science Medical Monitor. 2006; 12:BR341-349
  47. Couce ME, Esplen J, Teijeiro R, Achim C,  Burguera B. Ghrelin has trophic effects on human fetal neuroglial cells. An in vitro study. Obesity and Metab. 2006;2:87-94
  48. Llompart-Pou JA, Raurich JM, Ibanez J, Burguera B, Barcelo A, Ayestaran JI, Perez-Barcena J.Relationship between plasma adrenocorticotropin hormone and intensive care unit survival in early traumatic brain injury. J Trauma. 2007; 62:1457-61.
  49. Llompart-Pou JA, Perez-Barcena J, Raurich JM, Burguera B, Ayestaran JI, Abadal JM, Homar J, Ibanez J. Effect of barbiturate coma on adrenal response in patients with traumatic brain injury. J Endocrinol Invest. 2007; 30:393-8.
  50. Burguera B, Agusti A, Arner P, Baltasar A, Barbe F, Barcelo A, Breton I, Cabanes T, Casanueva FF, Couce ME, Dieguez C, Fiol M, Fernandez Real JM, Formiguera X, Fruhbeck G, Garcia Romero M, Garcia Sanz M, Ghigo E, Gomis R, Higa K, Ibarra O, Lacy A, Larrad A, Masmiquel L, Moizé V, Moreno B, Moreiro J, Ricart W, Riesco M, Salinas R, Salvador J, Pi-Sunyer FX, Scopinaro N, Sjostrom L, Pagan A, Pereg V, Sánchez Pernaute A, Torres A, Urgeles JR, Vidal-Puig A, Vidal J, Vila M. Critical assessment of the current guidelines for the management and treatment of morbidly obese patients. J Endocrinol Invest. 2007 30:844-52.
  51. Riesco M,  Pagan A, Piñero E, Barcelo A, Garcia Sanz M, Moreiro J, Pereg V, Urgeles JR, Vila M, Vidal-Puig A, Salinas R, Burguera B. The development of type 2 Diabetes Mellitus in the context of morbid obesity is not related to differences in inflammatory status. Obesity and Metabolism 2008; 4: 193-198.
  52. Riesco M; Barceló A; Vila M; Belmonte M; Ruiz O; Lopez-Escribano H; Madany E; and Burguera B. Plasma levels of visfatin and obestatin in morbidly obese subjects with and without T2 diabetes mellitus. Obesity and Metabolism 2009; 5: 9-12.
  53. Tur J, Burguera B. Therapeutic evaluation of the morbidly obese patient. Endocrinol Nutr. 2009;56:452-8
  54. Llompart-Pou JA, Pérez, Gerardo; Pérez-Bárcena, J; Brell, M; Ibáñez, J; Riesco, M;  Abadal, J; Homar, J; Marsé, P;  Ibáñez, J; Burguera, B; Raurich, J. traumatic brain injury, cerebral microdialysis, total serum cortisol, brain interstitial cortisol. J Endocrinol Invest En prensa.
  55. Frontera M, Burguera B.  Papel del Intestino Delgado en la Resolución de la DMT2 después de cirugía bariátrica. Educación Diabetológica Profesional. XIX  2 2009. 37-42
  56. Llompart-Pou JA, Pérez G, Pérez-Bárcena J, Brell M, Ibáñez J, Riesco M, Abadal JM, Homar J, Marsé P, Ibáñez J, Burguera B, Raurich JM. Correlation between brain interstitial and total serum cortisol levels in traumatic brain injury. A preliminary study. J Endocrinol Invest. 2010; 33:368-72.
  57. Llompart-Pou JA, Pérez G, Raurich JM, Riesco M, Brell M, Ibáñez J, Pérez-Bárcena J, Abadal JM, Homar J, Burguera B Loss of cortisol circadian rhythm in patients with traumatic brain injury: a microdialysis evaluation. Neurocrit Care. 2010.13:211-6
  58. Brell M, Ibáñez J, Felpete A, Burguera B, Frontera M, Couce ME. Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas.  Brain Tumor Pathol. 2011 Feb 18.
  59. Fiol M, Amézaga R, Arós F, Burguera B, Sala J, Bruguera J, Valle V, Sanz G, Covas MI, Fitó M, Martí H, Elosua R, Schröder H, Marrugat J. Body mass index in the prognosis of first myocardial infarction]. Med Clin (Barc). 2010; ;135:631-6
  60. Tur J, Escudero A, Iglesias L, Alos M, Luque L, Burguera B.Key points in the start and conduct of a clinical trial. From question to reality in an investigator-initiated clinical trial (I).Endocrinol Nutr. 2011; 58:291-8.
  61. Tur J, Alòs M, Iglesias L, Luque L, Colom A, Escudero A, Martínez D, Pagán A, Ugarriza E, Frontera M, Nicola G, Palomero A, Tofé S, Urgeles JR, Barceló A, Couce M, De La Peña M, Fiol M, Cortés B, Terés E, Tumbarello A, Álvarez C, Salinas R, Pereg V, González X, Burguera B . TRAMOMTANA (Tratamiento Multidisciplinar de la Obesidad Mórbida: Medicamentos, Terapia de comportamiento, Apoyo Nutricional y Actividad física). De la pregunta a la realidad de un ensayo clínico investigador iniciado (II). Endocrinol Nutr. 2011; 58:299-307
  62. Burguera B; Colom A; Piñero E; Yanez A; Caimari M, Juan Tur J,  Frontera M, Couce M,  Cardó E,  Aguiló A, Burguera  A,  Cabeza E. ACTYBOSS: Activity, Behavioral Therapy in Young Subjects. After-school intervention Pilot Project on obesity prevention. Incentive-driven children obesity prevention program. Obes Facts. 2011;4 :400-6.
  63. Piérola J, Alemany A, Yañez A, de-la-Peña M, Sánchez-de-la-Torre M, Esquinas C, Pérez-Gutierrez C, Burguera B, Barbé F, Barceló A NADPH oxidase p22phox polymorphisms and oxidative stress in patients with obstructive sleep apnoea.Respir Med. 2011; 105:1748-54
  64. Llompart-Pou JA, Fernández-de-Castillo AG, Pérez-Bárcena J, Marsé P, Rodríguez-Yago M, Barceló A, Raurich JM. Stress hyperglycaemia in critically ill patients: Potential role of incretin hormones; a preliminary study.Nutr Hosp. 2012; 27:130-7.
  65. Lecube A, Burguera B, Rubio MA; en nombre del Grupo de Trabajo de Obesidad de la Sociedad Española de Endocrinología y Nutrición (GOSEEN). Breaking therapeutic inertia: should metabolic surgery be considered one more option for the treatment of type 2 diabetes mellitus?Endocrinol Nutr. 2012 Apr 13.
  66. Burguera B, Ruiz de Adana JC. Long term effects of bariatric surgery.Cir Esp. 2012; 90 :275-276.
  67. Burguera B, Colom A, Piñero E, Yanez A, Caimari M, Tur J, Frontera M, Couce M, Cardo E, Aguiló A, Burguera A, Cabeza E ACTYBOSS: activity, behavioral therapy in young subjects--after-school intervention pilot project on obesity prevention.Obes Facts. 2011; 4:400-6.
  68. Caixàs A, Lecube A, Morales MJ, Calañas A, Moreiro J, Cordido F, Díaz MJ, Masmiquel L, Moreno B, Vidal J, Goday A, Arrizabalaga JJ, García-Luna PP, Iglesias P, Burguera B, Rubio MA, Monereo S; Group for the Study of Obesity of the Spanish Endocrinology and Nutrition Society (SEEN), Crosby RD, Kolotkin RL. Weight-related quality of life in Spanish obese subjects suitable for bariatric surgery is lower than in their North American counterparts: a case-control study.Obes Surg. 2013; 23 :509-14. doi: 10.1007/s11695-012-0791-0
  69. Tur, J. J., Escudero, A. J., Alos, M. M., Salinas, R., Terés, E., Soriano, J. B., Nicola, G., Urgelés, J. R., Pagán, A., Cortes, B., González, X. and Burguera, B. (2013), One year weight loss in the TRAMOMTANA study. A randomized controlled trial. Clinical Endocrinology. doi: 10.1111/cen.12109
  70. Tur JJ, Escudero AJ, Romaguera D, Burguera B.How can we predict which morbidly obese patients will adhere to weight-loss programs based on life style changes?Endocrinol Nutr. 2013 Jun-Jul;60:297-302
  71. Caixàs A, Lecube A, Burgura B et al; Obesity Working Group of the Spanish Society of Endocrinology and Nutrition (GOSEEN). Where are obese people happier?Endocrinol Nutr. 2014; 61(1):1-2. 2013.
  72. Vázquez C, Botella-Carretero JI, Corella D, Ros E, Salas-Salvadó J, Burguera B, Estruch R, Fernández-Real JM, Fuentes F, Pastor O, and Felipe F Casanueva. White fish reduces cardiovascular risk factors in patients with Metabolic Syndrome. The multicenter WISH-CARE study* Nutr Metab Cardiovasc Dis. 2014 Mar; 24:328-35.
  73. Ali Aminian M.D.,Stacy A Brethauer  M.D., John P Kirwan Ph.D. Sangeeta R Kashyap M.D., Bartolome Burguera M.D. Ph.D., Philip R Schauer M.D.How Safe is Metabolic/Diabetes Surgery?.RESEARCH LETTER in Press Diabetes, Obesity and Metabolism. 2015
  74. Ali Aminian M.D.,Stacy A Brethauer  M.D., John P Kirwan Ph.D. Sangeeta R Kashyap M.D., Bartolome Burguera M.D. Ph.D., Philip R Schauer M.D.. Outcomes of bariatric surgery in type 2 diabetic patientswith diminished pancreatic secretory reserve. Acta Diabetol DOI 10.1007/s00592-014-0642-7
  75. Bartolomé BurgueraMD, PhD; Juan Jesús Tur PhD; Antonio Jorge Escudero BS; María Micaela MD; Alberto Pagán MD; Baltasar Cortés BS; Xavier Francesc González MD, PhD; Joan B. Soriano MD, PhD.AN INTENSIVE LIFE STYLE INTERVENTION IS AN EFFECTIVE TREATMENT OF MORBID OBESITY. THE TRAMOMTANA Study: A Two-year Randomized Controlled Clinical Trial.Submitted.
  76. Albert Goday, Diego Bellido, Ignacio Sajoux,  Basilio Moreno, Pedro P. García Luna, Bartolome Burguera and Felipe Casanueva. Short-term safety and tolerability of a low-carbohydrate-ketogenic diet interventional weight loss, program versus hypocaloric diet in patients with type 2 diabetes mellitus. Submitted.

Invited, Non-Peer Reviewed

  1. Burguera B. Couce ME. Lloyd RV. Leptin receptor and the Brain. A tale of body weight regulation.2001 Curr Opin Endocrinol Diabetes. 7:225-230
  2. Burguera B, Couce ME.  Leptin Access into the Brain: a Saturated Transport Mechanism in Obesity. 2001 Physiol and Behavior.74:717-20.
  3. Burguera B. Es la Cirugía Bariatrica el único tratamiento para la Obesidad Mórbida? Monográfico Actualización de la Obesidad. Revista Hormona y Factores de Crecimiento.  In press.
  4. Estefanía Piñero Bartolomé Burguera. Epidemia de Obesidad en EEUU y la realidad Española. Libro Ponencias. IV Reunion Internacional “ La alimentación y la Nutricion del Siglo XXI. Baiona. Nov 2006
  5. Gonzalez Boillos M, Pereg V, Burguera B. Novedades en Terapia hipoglucemiante. Fármacos con acción incretina. Endocrinol Nutr, 2007; 54:1-000
  6. Quevedo J, Tur J, Soler G, Burguera B. Utilidad de los fármacos antiobesidad en el tratamiento de la diabetes tipo 2». Avances en Diabetología. 26: 161-166, 2010
  7. Burguera B. Diabetes Mellitus Tipo 2¿Debe ser la cirugía metabólico parte delarmamentarium terapeútico?Medicina Balear 2012; 27; 5-8
  8. Luque L, Riera A, Burguera B: “Cirugía bariátrica y diabetes mellitus tipo 2 ¿son todas las técnicas quirúrgicas iguales?Avances en Diabetología,2013

Book Chapters

  1. Casabiell X, Burguera B, Muruais C, Garcia RVG, Casanueva FF, Dieguez C, Prolactina Cortada: Estudio de sus Mecanismos de Formaciòn in Vitro. In: Forteza J, editor. IV FISss Annual Meeting, 1989; 88-104.
  2. Casanueva FF, Burguera B, Casabiell X, Alvarez C, Muruais C, Dominguez F, Dieguez C.  Levels of neuroendocrine and pharmacologic regulation of growth hormone secretion.  In: Muller EE MacLeod RM, editors. Neuroendocrine Perspectives, Vol 1. Amsterdam: Elsevier, 1989; 177-188.
  3. Muruais C, Burguera B, Casabiell X, Peñalva A, Mallo F, Casanueva FF, Dieguez C.  Administration of glucocorticoids and GH secretion in man.  In: Casanueva FF, Dieguez C, editors. Recent Advances in Basic and Clinical Neuroendocrinology.Excerpta medica. Amsterdam: Elsevier, 1990; 233-239.
  4. Burguera B, Caro JF. Alterations in insulin receptors and glucose transporters in obesity and type II diabetes.  In: Shafrir E, editor.  Frontiers in Diabetes Research: Lessons from Animal Diabetes, Vol. 6. Oxford: Smith-Gordon and Company Ltd., 1990: 269-276.
  5. Mallo F, Alvarez C, Burguera B, Lamas JA, Señaris R, Dominguez C. Regulation of growth hormone secretion by thyroid hormones and estrogens. In: de la Cruz LF, Garcia Lara MT, editors.Recent Advances in Growth and Reproduction.Santiago: University Press, 1991; 55-63.
  6. Cordido F, Mallo F, Casabiell X, Alvarez C, Señaris R, Burguera B, Dieguez C, Casanueva FF. In: de la Cruz LF, Garcia Lara MT, editors. Neuroregulation of GH Secretion in Obesity.  Santiago: University Press, 1991; 93-103.
  7. Burguera B, Muruais C, Casabiell X, Mallo F, Alvarez C, Dieguez C, Casanueva FF. Dual and selective effect of dexamethasone upon GH secretion. In: Thorner FH, editor. Ares-Serono Symposia, Vol 58.  New York: Raven Press 1989; 90-95.
  8. Burguera B, Couce ME, Caro JF. Papel del IGF-II R en la regeneracion hepatica. In: Dieguez C, Casanueva FF, editors. Advances Endocrinologia Molecular y Celular. Madrid: Fundación Ramon Areces, 1992; 221-236.
  9. Burguera B, Parzianello N, Caro JF. Estudio de los niveles de GLUT-2 in NIDDM.  In: Dieguez C, Casanueva FF, editors.Fronteras en Endocrinologia. Madrid: Diaz Santos, 1992; 19-29.
  10. Burguera B, Werner H, Couce M, Robert CT, Jr., LeRoith D, Caro JF. Physiology of the insulin-like growth factor I and insulin-like growth factor II/Mannose 6-phosphate receptors. In: de la Cruz LF, editor. Regulation of Growth Hormone and Somatic Growth.  Amsterdam: Elsevier, 1992; 271-294.
  11. Burguera B. Obesity Prevention. Endo text. (Eds. Jose Caro and Leslie DeGroot). WWW.ENDOTEXT.ORG
  12. Horowitz M. Levy E, Genevro J, Kassam A, Burguera B. Petrosal Sinus Sampling For Cushing’s Disease.. Book Chapter in Interventional Radiology. (Horowitz M. Ed). 2005
  13. Josefina Olivares, Bartolome Burguera. Pubertad y Homeostasis Metabólica. Monografía PUBERTAD.  (Editores: C. Dieguez/R. Yturriaga). 2006
  14. Material Educativo para pacientes de Cirugía Bariatrica. Editado por Novartis Laboratorios. 2006
  15. Diaz S, Burguera B. Actitud ante el Debut de una Diabetes Mellitus. Perspectiva General del Tratamiento. La Diabetes Mellitus en la Practica Clinica. (Ed. Javier Tebar/Fernando Escobar). 2009
  16. Burguera B. Obesidad Mórbida: Tratamiento quirúrgico y sus repercusiones nutricionales y metabólicas. Manual de Endocrinologia para residentes. Ed. Sociedad Española de Endocrinologia. 2009 
  17. Burguera B. Tur J. Medical Management of Obesity". 2nd edition of Minimally Invasive Bariatric Surgery. Springer Science + Business Media, (Ed Philip R. Schauer, Buce D. Schirmer, and Stacy A. Brethauer) 2014

Editorials

    Burguera B, Ruiz de Adana JC. Long term effects of bariatric surgery.Cir Esp. 2012; 90 :275-276.

Letters

    Burguera B& Couce ME. 2000. Leptin access into the brain: a saturated transport system vs. a post-receptor defect in obesity. J Clin Invest. e-letter.

Abstracts

  1. Casanueva FF, Borras C, Burguera B, Muruais C, Fernandez M, Devesa J. Steroids and neuroendocrine function in anorexia nervosa.VII World Steroids Congress, Madrid, Spain, 1986.
  2. Dieguez C, Villaneuva L, Diaz Y, Burguera B, Alvarez C, Scanlon M, Casanueva FF. Free fatty acids (FFA) inhibit GH secretion at pituitary level. First European Congress of Endocrinology, Copenhagen, Denmark, 1987.
  3. Peñalva A, Burguera B, Casabiell J, Mallo F, Casanueva FF, Dieguez C. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycaemia on GHRH-induced GH secretion in man. III International Meeting of Neuroendocrinology, Barcelona, Spain, 1988.
  4. Casabiell X, Burguera B, Muruais C, Alvarez C, Dieguez C, Casanueva FF. Cleaved PRL: mechanism of in vitro formation. III International Meeting of Neuroendocrinology, Barcelona, Spain, 1988.
  5. Casanueva FF, Burguera B, Casabiell X, Peñalva A, Dieguez C. Neuroregulation of prolactin (PRL) secretion in normal human subject. Eighth International Congress of Endocrinology, Japan, 1988.
  6. Burguera B, Muruais C, Dieguez C, Casanueva FF. Dual and selective effect of dexamethasone upon GH secretion in man.International Symposium on Hormonal Regulation of Growth, Vienna, Austria, 1988.
  7. Burguera B, Muruais C, Dieguez C, Casabiell X, Casanueva FF. Potent stimulatory effect of glucocorticoids on growth hormone (GH) secretion in man.71st Annual Meeting of the Endocrine Society, Seattle, WA, 1989
  8. Dieguez C, Burguera B, Mallo F, Alvarez C, Sanchez-Franco F, Casanueva FF. Dual effects of glucocorticoids on the neuroregulation of growth hormone secretion in the rat.9th International Symposium of the Journal of Steroid Biochemistry, Spain, 1989.
  9. Muruais C, Burguera B, Casabiell X, Peñalva A, Casanueva FF, Dieguez C. Acute administration of glucocorticosteroids (GC): a new and peculiar stimulus of growth hormone (GH) secretion in man. 4th Meeting of the European Neuroendocrine Association, Spain, 1989.
  10. Benitez L, Mallo F, Alvarez C, Burguera B, Sanchez-Franco F, Dieguez C. Effect of Bombesin on in vitro GH secretion and its modulation by estrogens. 4th Meeting of the European Neuroendocrine Association, Spain, 1989.
  11. Alvarez C, Burguera B, Mallo F, Benitez L, Sanchez-Franco F, Casanueva FF, Dieguez C. Effect of acute and chronic dexamethasone administration on in vivo GH responses to GHBM in normal and hypophysectomized-transplanted rats.4th Meeting of the European Neuroendocrine Association, Spain, 1989.
  12. Mallo F, Alvarez C, Burguera B, Benitez L, Lamas JA, Casanueva FF, Dieguez C. Modulatory role of peripheral signals on in vivo GH response to GHRP-6 in the rat.4th Meeting of the European Neuroendocrine Association, Spain, 1989.
  13. Werner H, Shen-Orr Z, Burguera B, Stannard B, Roberts CT Jr, LeRoith D. Experimental diabetes increases IGF-I receptor gene expression and binding in the rat kidney. 50th Annual Meeting of the American Diabetes Association, Atlanta, GA, 1990.
  14. Burguera B, Werner H, Sclar M, Roberts CT Jr, LeRoith D. IGF-II R gene expression during liver regeneration.50th Annual Meeting of the American Diabetes Association, Atlanta, GA, 1990.
  15. Burguera B, Werner H, Roberts CT Jr, Caro JF, LeRoith D. IGF II receptor gene expression during liver regeneration. II International Symposium on Endocrinology Under 35, Italy, 1990.
  16. Usala AL, Usala ST, Powel J, Madigan T, Cefalu W, Burguera B, Sinha MK. Intravenous (IV) but not subcutaneous (SC) IGF-I improves clinically severe insulin resistance (IR) in vivo and adipocyte IR in vitro. Symposium on Insulin IGFs and Their Receptors, Woods Hole, MA, 1992.
  17. Burguera B. Neuroregulation of appetite. 2nd Reunion Medicos Gallegos. Orense, Spain 1997
  18. Thomas T, Burguera B, Melton LJ, Atkinson EJ, Riggs BL, Khosla S. 1998. Fat body mass and bone mineral density are directly related both in women and in men, but serum leptin levels and bone mineral density are directly related only in women. Second Joint Meeting of the ASBMR and the IBMS. San Francisco, 1998
  19. Llompart Pou, JA, Pérez Aizcorreta O, Pérez Bárcena J, Raurich Puigdevall JM, Burguera Bartolomé*, Abadal Centellas JM, Homar Ramírez J, Ibáñez Juvé J. Congreso Nacional de Medicina Intensiva.2006
  20. Marga Frontera, Marta Couce, Ana Felpete, Bartolomé Burguera. STUDY ON THE EXPRESSION OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR IN HUMAN HYPOTHALAMUS. Comunicación Reunion CIBEROBN. La Toja Septimbre 09.
  21. Alvarez C, Burguera B, Casabiell X, Casanueva FF, Dieguez C. Estudio del papel regulador de los acidos grasos libres (FFA) sobre la secreción de GH. XXIII Reunión Nacional de la Sociedad Española de Endocrinologia, Granada, Spain, 1987.
  22. Burguera B, Muruais C, Tome M, Devesa J, Dieguez C, Casanueva FF. Dependiendo del tiempo de administración y dosis, dexametasona potencia o bloquea la secreción de GH inducida por GHRH. XXIII Reunión Nacional de la Sociedad Española de Endocrinologia, Granada, Spain, 1987.
  23. Muruais C, Burguera B, Casabiell X, Dieguez C, Casanueva FF. Estudio de la secreción adenohipofisaria ante stress psiquico . I Encontro Luso-Galaico de Endocrinologia, Oporto, Portugal, 1987.
  24. Casabiell X, Burguera B, Alvarez C, Dieguez C, Casanueva FF. Estudio de la influencia de los acidos grasos libres en la secreción de GH en la rata. I Encontro Luso-Galaico de Endocrinologia, Oporto, Portugal, 1987.
  25. Alvarez C, Burguera B, Casabiell X, Dieguez C, Casanueva FF. Formas moleculares de PRL. I Encontro Luso-Galaico de Endocrinologia, Oporto, Portugal, 1987.
  26. Muruais C, Peñalva A, Burguera B, Dieguez C. Papel de la somatostatina en el efecto inhibidor de los acidos grasos libres y la glucosa sobre la liberación de GH inducida por GHRH. VII Congreso nacional de Endocrinologia, Bilbao, Spain, 1988.
  27. Burguera B, Muruais C, Casabiell X, Alvarez C, Dieguez C, Casanueva FF. Control dual y selectivo de los glucocorticoids sobre la liberación de GH. VIII Congreso Nacional de Endocrinologia, Bilbao, Spain, 1988.
  28. Mallo F, Alvarez C, Burguera B, Benitez L, Ibañez R, Muruais C, Casanueva FF, Dieguez C. Papel modulador de los estrógenos sobre la neuroregulación de GH por GHRH, bombesina y neurotensina. II Congreso Luso-Galaico de Endocrinologia, Santiago, Spain, 1988.
  29. Peñalva A, Muruais C, Burguera B, Casabiell X, Dieguez C, Casanueva FF. La activación colinérgica central por piridostigmina induce una respuesta positiva de GH a dosis ineficaces de GHRH. II Congreso Luso-Galaico de Endocrinologia, Santiago, Spain, 1988.
  30. Zalvide J, Briones R, Señaris R, Burguera B, Dieguez C, Dominguez F. Efecto de la dexametasona sobre la producción de protimosina. II Congreso Luso-Galaico de Endocrinologia, Santiago, Spain, 1988.
  31. Burguera B, Raju SM, Abdallah S, Mooney M, Mustafa SJ, Caro JF. Does proinsulin crossreact with the IGF's receptors accelerating heart disease? 3rd Annual Research Day, Department of Medicine, ECU School of Medicine, Greenville, NC, 1989.
  32. Burguera B, Caro JF. Mechanism of insulin resistance in the liver of type-II diabetic patients.10th National Endocrine Meeting, Spain, 1991.
  33. Burguera B, Stanzak R, Slieker L, Leggett-Frazier N, Long S, Caro JF. Is the low level of Glut-2 gene expression present in impaired glucose tolerant patients (IGT) preventing or inducing non-insulin dependent diabetes mellitus? 73rd Annual Meeting of the Endocrine Society, Washington, DC, 1991.
  34. Stanzak R, Burguera B, Caro JF. Developmental regulation of GLUT-2 glucose transporter expression in the human liver.5th Annual Research Day, Department of Medicine, ECU School of Medicine, Greenville, NC, 1991.
  35. Burguera B. The regulation of GLUT-2 in the liver.Mid-Atlantic Diabetes Research Symposium at NIH, Bethesda, MD, 1991.
  36. Usala AL, Madigan T, Burguera B, Caro JF, Butler P. Insulin-like growth factor I (IGF-I) treatment for insulin resistant ketoacidosis in an adolescent girl with Type I diabetes mellitus. American Pediatric Society, Baltimore, MD, 1992.
  37. Usala AL, Madigan T, Burguera B, Caro JF, Powell J, Cunningham P, Butler P. Effect of IGF-I on lipolysis, ketogenesis and glycemia in an adolescent with Type I diabetes mellitus and massive episodic insulin resistance.74th Annual Meeting of the Endocrine Society, San Antonio, TX, 1992.
  38. Burguera B, Dudek RW, Stanzak R, Couce ME, Caro JF. GLUT-2 expression in NIDDM patients.6th Annual Research Day, Department of Medicine, ECU School of Medicine, Greenville, NC, 1992.
  39. Usala AL, Madigan T, Burguera B, Powell JC, Ricker AT, Usala SJ. Intravenous, but not subcutaneous, insulin-like growth factor I (IGF-I) induces sustained insulin sensitivity in severely resistant patients. American Pediatric Society, Washington, DC, 1993.
  40. Usala AL, Powell J, Madigan T, Burguera B, Usala SJ. Intravenous or subcutaneous IGF-I therapy induces symptomatic hypophosphatemia in patients with severe insulin resistance. 75th Annual Meeting of the Endocrine Society, Las Vegas, NV, 1993.
  41. Burguera B, Tapscott EB, Elton CW, Carey J, Usala AL, Pories WJ, Sakano K, Dohm GL. IGF-II stimulation of glucose uptake in human muscle is not mediated by the IGF-II receptor (IGF-II/Man 6-P R). 75th Annual Meeting of the Endocrine Society, Las Vegas, NV, 1993.
  42. Burguera B, Usala AL, Pories WJ, Dohm GL. IGF-II effect on glucose uptake in human muscle.7th Annual Research Day.Department of Medicine, ECU School of Medicine, Greenville, NC, 1993.
  43. Burguera B. Therapeutic effect of IGF-1 in diabetes.37th National Endocrine Society Meeting. Toledo, Spain, 1994.
  44. Burguera B, Usala AL. Clinical use of IGF-I as a novel therapy in the treatment of diabetic ketoacidosis and insulin resistance.TheConnecticut Chapter of the American College of Physicians. Trumbull,CT 1995.
  45. Burguera B, Couce ME, Parisi JE, Jensen MD, Lloyd RV. Localization of leptin receptor in the human brain. 79th Annual Meeting of the Endocrine Society, Minneapolis, 1997.
  46. Guo Z., Burguera B, Jensen MD Triglyceride synthesis rate in skeletal muscle measured using 13-C fatty acids. FASEB. New Orleans. 1997.
  47. Burguera B, Couce ME, Lamsam J, Jensen MD, Lloyd RV. The long form of the leptin receptor (OBpRb) is widely expressed in the human brain. 80th Annual Meeting of the Endocrine Society, New Orleans, 1998
  48. Thomas T, Gori F, Jensen MD, Burguera B, Riggs BL. 1998. Mechanism of fat mass effects on bone mass: leptin as a promoter of osteoblastic progenitor differentiation. 80th Annual Meeting of the Endocrine Society, New Orleans, 1998
  49. L. Jin, Burguera B, Couce ME, Lamsam J, K. Kovacs, Lloyd RV. Leptin receptor (OB-Rb) expression in normal and neoplastic human pituitaries. Regulation of pituitary cell proliferation by leptin..80th Annual Meeting of the Endocrine Society, New Orleans, 1998
  50. Burguera B ,Thomas T, Gori F, Evans G, Lamsam J, Laakso K, Khosla S, Riggs, LW, Turner RT. Leptin inhibits bone resoption in vivo. NAASO Annual Meeting. Charleston, 1999
  51. Burguera B, Curran G, Couce ME, Lamsam J, Cleary M, Poduslo J. Obesity is associated with a decreased of leptin transport across the blood brain barrier and up regulation of leptin receptor in the hypothalamus. NAASO Annual Meeting. Charleston, 1999
  52. Couce ME., Espleen J, Brunetto A, Kates C, Green D, Achim C, Burguera B. Both, Leptin and Ghrelin have a trophic effect on developing neurons and glial cells. NAASO Annual Meeting. Quebec 2000.
  53. Couce ME, Cottam DR, Teijeiro R, Esplen J, Schauer P, Burguera B. Plasma Ghrelin levels after gastric bypass Surgery. American Diabetes Association's 63rd Scientific Sessions. June 2003. New Orleans, Louisiana.
  54. Couce ME, Teijeiro R, Esplen J, Burguera B. Human Obesity Is Associated with Increased Hypothalamic Synthesis of Ghrelin American Diabetes Association's 63rd Scientific Sessions. June 2003. New Orleans, Louisiana.
  55. Couce ME, Goodpaster B, Teijeiro R, Esplen J, Cameron J, Burguera B. Impact of Resistance Training on Ghrelin Levels in Primates. American Diabetes Association's 63rd Scientific Sessions. June 2003. New Orleans, Louisiana.
  56. Couce ME, Teijeiro R, Esplen J, Burguera B. The role of central ghrelin in human obesity American Society of Neuropathology. June 2003. Orlando, Florida
  57. Llompart Pou, JA, Pérez Aizcorreta O, Pérez Bárcena J, Raurich Puigdevall JM, Burguera Bartolomé*, Abadal Centellas JM, Homar Ramírez J, Ibáñez Juvé J. Congreso Nacional de Medicina Intensiva. 2006
  58. *Tur J, Burguera B, Escudero AJ, Alós MM, Ugarriza E, Luque L, Pereg V, Urgelés JR, Tofe S, Iglesias L, Cañellas F, Couce M, Guevara R, Sampol M, Palomero A, Cortés B, Colom A, Martínez D, González X. Tratamiento Multidisciplinar de la Obesidad Mórbida: Terapia de Conducta, Nutrición y Actividad Física. El Estudio TRAMOMTANA.. Endocrinol Nutr. 2011; 58, (Espec Cong) 1.
  59. *Escudero AJ, Tur J, Alós MM, Ugarriza E, Luque L, Pereg V, Urgelés JR, Tofe S, Iglesias L, Cañellas F, Couce M, Guevara R, Sampol M, Palomero A, Cortés B, Colom A, Martínez D,Burguera B. ATTOM: Abordaje Telemático Interdisciplinar de la Obesidad Mórbida” Endocrinol Nutr. 2011; 58, (Espec Cong) 65.
  60. *Colom A, Cabeza E, Yáñez A, Frontera M, Cortés B, Martínez D, Burguera A, Luque L, Iglesias L, Escudero AJ, Tur J, Caimari M, Cardo E, Aguiló A, Burguera B. Base-Line of ACTYBOSS (Activity, Conductual Therapy in Young Subjects) Prospective, Multicenter, Cluster randomized, paired and controlled, after-school community trial on Obesity Prevention. ” Endocrinol Nutr.2011; 58, (Espec Cong) 86.
  61. *Luque L, Iglesias L, Burguera B, Colom A, Tur J, Escudero AJ, Cortés B, Martínez D. Estudio Ses Passes Ses Pases. Endocrinol Nutr. 2011; 58, (Espec Cong) 92.
  62. *Tur J, Burguera B, Escudero AJ, Alós MM, Ugarriza E, Luque L, Iglesias L, Palomero A, Colom A, Cañellas F. Factores Predictivos de éxito/fracaso en la terapia interdisciplinar intensiva en pacientes obesos mórbidos participantes en el Estudio TRAMOMTANA. Rev Esp Obes. 2011; 9, 2, 115.
  63. *Escudero AJ, Burguera B, Alós MM, Ugarriza E, Luque L, Iglesias L, Palomero A, Colom A, Cañellas F, Tur J. Sistema de análisis de test psicométricos y de calidad de vida relacionada con la salud mediante herramientas de predicción en el estudio TRAMOMTANA. Rev Esp Obes. 2011; 9, 2, 104.
  64. *Alós MM, Tur J, Escudero AJ, Ugarriza E, Colom A, Cortés B, Iglesias L, Martínez D, Luque L, Burguera B. estandarización de una pauta de preparación a la incorporación de actividad física en una población de obesos mórbidos participantes en el Estudio TRAMOMTANA. Rev Esp Obes. 2011; 9, 2, 116.
  65. Ali Aminian, Christopher R Daigle, John P Kirwan, Bartolome Burguera, Sangeeta R Kashyap, Stacy A Brethauer, Philip R Schauer. Outcomes of Bariatric Surgery in Diabetic Patients with Diminished Pancreatic Secretory Reserve.American Diabetes Association Meeting. San Diego. 2014.

Presentations

  1. International Symposium on Hormonal Regulation of Growth
    Austria, 1988
  2. Sociedad Española de Endocrinologia, Congreso Nacional Santiago, Spain, 1991
  3. Post-Graduate Course onMolecularMechanisms of the Endocrine System,
    Foundacion Ramon Areces, La Toja, Spain, 1991
  4. ECU Diabetes Series, Greenville, NC, 1992
  5. Sociedad Española de Endocrinologia, Congreso Nacional. Toledo, 1994
  6. The Connecticut Chapter ofthe American College ofPhysicians, 1995
  7. 2nd Reunión Medicos Gallegos, Orense, España, 1997
  8. Orange County Endocrine Society, California, 1999
  9. Boston University.Obesity Center, 1999
  10. Curso de Post-Grado enMolecularMechanismosdel Systema Endocrino,
    Foundacion Ramon Areces. Orense, 1999
  11. The Society for the StudyofIngestive Behavior, Meeting annual. Dublin, 2000
  12. Endocrine Grand Rounds. Boston University. Boston, 2000
  13. Obesity and Diabetes, Diabetes In Office Practice, Dedham. Boston University. Boston, 2000
  14. Diabetes 2001. State of the Artin Diabetes, Obesity and Nutrition, Sociedad Española de Diabetes, Madrid, 2001
  15. The Obesity Epidemic, 'Practical Treatment of Obesity:Medical and Surgical Options,'UPMC Pittsburgh, 2001
  16. Pathophysiology of obesity: Diabetes State of the Artin Diabetes,Obesity and Nutrition,Sociedad Española de Obesidad. Madrid, 2001
  17. “Obesity therapy,” Division of Endocrinology Grand Rounds, Boston University, 2001
  18. Tratamiento de la Obesidad, Hospital Clinico, Madrid, 2001
  19. “Therapeutical approach to morbid obesity,” Medicine Grand Rounds, UPMC. Pittsburgh,2002
  20. “Ethiopathogenesis and therapy of obesity,”Women Health Program. UPMC. Pittsburgh,2002
  21. “ Impact of weight loss on obesity comorbidities,”Practical treatment of obesity medical and surgical options,UPMC Obesity Course, 2002
  22. “ Obesity, Obesity, is it diet or genes?,”Internal Medicine Review Course, UPMC Obesity Course 2002
  23. Update on Medical Management of Obesity, Morbid Obesity Symposium, Lake Tahoe, California Feb 2003
  24. Simposio "Diabetes, de la enfermedadaterosclerótica a la enfermedadcardiovascular," Hospital Clinico, Barcelona, May 2003
  25. Sociedad Española de Endocrinologia, Congreso Nacional Badajoz, Spain, May 2003
  26. IFATS Symposium, Neuroregulation of appetite, Mallorca. Spain, May 2003
  27. Obesity Therapy, 4th Annual MIS Symposium, Whistler, British Columbia, February 2004
  28. Curso de Post-Grado enMolecularMechanismosdel Systema Endocrino, Foundacion Ramon Areces, Santiago de Compostela, November 2004
  29. II SALON INTERNACIONAL DE LA SALUD, Mórbid Obesity : an endocrinological perspective,Santiago, March 2005
  30. Congreso Nutrición Salud Sociedad, Impact of weight loss on type 2 diabetes Mellitus Bilbao, June 2005
  31. Summer Course El Escorial, Impacto de la Cirugía Bariatrica sobre laDiabetes Tipo 2,Madrid, July 2005
  32. Neuroregulacion de Apetito, Reunión sobre Obesidad Mórbida de la Fundación de Investigación Científica de laMutua Madrileña, Madrid, October 2005
  33. Conferencia de Clausura de la SociedadEspañola de Obesidad, Epidemia de Obesidad. Lecciones Americanaspara una Realidad Española, Murcia, October 2005
  34. Morbid Obesity: an endocrinologicalPerspective, Hospital Universitario de Las Palmas, November 2005
  35. European Health Forum, Obesity, a public health problem, Santiago, December 2005
  36. Residents Course. Sociedad Españolade Endocrinologia, February 2006
  37. Obesity and cardiovascular risk.Congreso Sociedad Catalana de Diabetes, March 2006
  38. New obesity therapies, Congreso de Obesidad, Universidad de Navarra, March 2006
  39. Ghrelin and bariatric surgery, Hospital Clinic, Barcelona, April 2006
  40. Director Internacional Symposium on Morbid Obesity: “Morbid Obesity an Interdisciplinary Approach,” Palma, October 2006
  41. Academia Medica de Baleares, Reunión de Obesidad, Palma, October 2006
  42. International Conference on New Trendsin the Management of Morbid Obesity, Cambios Hormonales después de la Cirugía, Barcelona, November 2006
  43. IV Reunion Internacional “ La alimentacióny la Nutricion del Siglo XXI, Lecciones americanas para la realidad Española, Baiona, November 2006
  44. VI Congreso Sociedad Canaria deEndocrinología y Nutrición, La Palma, April 2007
  45. Endocrine Issues after Bariatric Surgery, European Congress of Endocrinology, Budapest, May 2007
  46. Nutrición en Cirugia Bariatrica, “ Curso de Nutricion Enteral parafarmacéuticos Hospitalarios,”Palma, November 2007
  47. 11th Mayo Endocrine Course, Evaluation of the morbidly obese patient, Palma de Mallorca, April 2008
  48. Jornadas de InvestigaciónIlles Balears, Investigación en Hospital Son Dureta, Palma de Mallorca, June 2008
  49. Chairman Mesa Obesidad Morbida, Congreso DIABESITY, Santiago de Compostela, October 2008
  50. Chairman Mesa diabetesy Obesidad Morbida, Symposium Obesidad MórbidaMutua Madrilena Madrid, November 2008
  51. Reunion Sociedad Balear de Hipertensión, Obesidad e hipertensión, Palma de Mallorca, November 2008
  52. 1er Curso Avanzado Obesidad, Nuevos tratamientos Obesidad, Sociedad Española de Obesidad,Madrid, February 2009
  53. Moderador y speaker, Symposium Diabesity, Sociedad Española de Diabetes, Tenerife, March 2009
  54. Congreso Sociedad Española de Endocrinologia, Obesity associated to antipsichotic therapy, Zaragoza, June 2010
  55. Reunión Anual CIBER Obesidad, “TRAMOMTANA and ACTYBOSS,” September 2010
  56. Congreso Sociedad Española de Obesidad, Moderador Mesa sobre Diabesidad. La Coruña, October 2010
  57. III Congreso Nacional de Laboratorio Clínico, Regulación de apetito, Obesidad y apnea del sueño Valencia, October 2010
  58. 4º Curso de Avances en el tratamientode la Obesidad, Fundacion Médica Mutua Madrileña, Tratamiento Médico Obesidad Mórbida, Madrid, October 2010
  59. Congreso Sociedad Balear de Cardiología, Impacto de la pérdida de peso sobre el RCV, Palma, October 2010
  60. Diabesity Novo Nordisk Symposium, Incretins and bariatric surgery, Iguazú. Argentina, March 2011
  61. Chairman Symposium on hyperproteinDiets, Spanish Endocrine Society Meeting, Santiago, May 2011
  62. Spanish Endocrine Society Course, Diabetes and bariatric surgery, Madrid, October 2011
  63. Spanish Obesity Society Meeting, Chairman Behavioral therapy and obesity, October 2011
  64. Diabesity International Symposium, Debate: VLCD, Sevilla, November 2011
  65. Galician Medical Association, Diabetes and bariatric surgery, Salvador de Bahia, Brasil, April 2012
  66. Spanish Obesity Society Review Course, Closing Lecture, TRAMOMTANA:Behavioral therapy and obesity, El Escorial, Madrid, September 2012
  67. Madrid Real Academia de Medicina, Life style interventions in Obesity Therapy, October 2012
  68. Medical Therapy of Morbid Obesity. Grand Rounds. Mayo Clinic. August. 2012
  69. Medical Approach to Morbid Obesity. Grand Rounds. Cleveland Clinic. January. 2013
  70. Life Style Interventions as treatment of Morbid Obesity.Cleveland Clinic Obesity Summit. Oct 13
  71. TRAMOMTANA: Interdisciplinary therapeutic approach to Morbid obesity. VII Latino Metabolic Meeting. San Antonio. TXNovember.2013
  72. Lecture on Bariatric Surgery to Graduate Students MMED52. Course Molecular mechanism in Human Disease. Cleveland Clinic.Lerner College of Medicine. Nov. 2013
  73. Obesity therapy. Universidad Nebrija. Ciencias de la Salud. Madrid April. 2014
  74. Novo Nordisk Lifecycle Management Advisory Board. New York City. August 14th -16th. 2014
  75. What to do with morbidly obese patients who do not respond to bariatric surgery? Obesty Symposium. Mutua Madrilena Medical Fundation. Madrid. October 2014
  76. Aspectos clínico-prácticos: Nuevos enfoques en el abordaje médico del tratamiento de la obesidad mórbida.8th. Curso Internacional sobre Obesidad.  MIAMI, FLORIDA November. 2014
  77. Medical Therapy Morbid Obesity. Congreso Panamericano de Medicina Interna. Los Cabos, Mexico. November 2014.
  78. Hispanic Health Committee of the Cleveland Hispanic Roundtable. Keynote speaker. Obesity Prevention and Treatment. Cleveland. April 2015

Burguera Bartolome

Director of Obesity Program

 

  • : 216.442.5663

  • DEPARTMENTDirector of Obesity Program
    Cleveland Clinic

  • COUNTRYUSA